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Objective: Assess current clinical practices for uveal melanoma (UM) and the impact of 
molecular prognostic testing on treatment decisions.
Design: Cross-sectional survey and sequential medical records review.
Participants: Ophthalmologists who treat UM.
Methods: (A) Medical records review of all Medicare beneficiaries tested by UM gene expres-
sion profile in 2012, conducted under an institutional review board-approved protocol. (B) 109 
ophthalmologists specializing in the treatment of UM were invited to participate in 24-question 
survey in 2012; 72 were invited to participate in a 23-question survey in 2014.
Main outcome measures: Responses analyzed by descriptive statistics, frequency analyses 
(percentages, Tukey, histograms), and Fisher’s exact test. Descriptive presentation of essay 
answers.
Results: The review of Medicare medical records included 191 evaluable patients, 88 (46%) 
with documented medical treatment actions or institutional policies related to surveillance 
plans. Of these 88, all gene expression profiling (GEP) Class 1 UM patients were treated with 
low-intensity surveillance. All GEP Class 2 UM patients were treated with high-intensity 
surveillance (P0.0001 versus Class 1). There were 36 (19%) with information concerning 
referrals after initial diagnosis. Of these 36, all 23 Class 2 patients were referred to medical 
oncology; however, none of the 13 Class 1 patients were referred (P0.0001 versus Class 1). 
Only Class 2 patients were recommended for adjunctive treatment regimens. 2012 survey: 50 
respondents with an annual median of 35 new UM patients. The majority of respondents (82%) 
performed molecular analysis of UM tumors after fine needle biopsy (FNAB); median: 15 
FNAB per year; 2014 survey: 35 respondents with an annual median of 30 new UM patients. 
The majority offered molecular analyses of UM tumor samples to most patients. Patients with 
low metastatic risk (disomy 3 or GEP Class 1) were generally assigned to less frequent (every 
6 or 12 months) and less intensive clinical visits. Patients with high metastatic risk (monosomy 
3 or GEP Class 2) were assigned to more frequent surveillance with hepatic imaging and liver 
function testing every 3–6 months. High-risk patients were considered more suitable for adju-
vant treatment protocols.
Conclusion: The majority of ophthalmologists treating UM have adopted molecular diagnostic 
tests for the purpose of designing risk-appropriate treatment strategies.
Keywords: uveal melanoma, gene expression profiling (GEP), Medicare, molecular diag-
nostic test
Introduction
The most common primary intraocular cancer in the United States is uveal melanoma 
(UM), the second most frequent subcategory of melanoma.1 New UM cases occur at 
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a rate of ~4.3 per million per year; UM has the distinction of 
being one of the few clinically-diagnosed malignancies.1–5 In 
addition, tumor tissue is rarely archived, because the majority 
of UM patients receive eye-sparing treatment of the primary 
tumor. Unfortunately, although less than 4% of patients have 
detectable metastatic disease at the time of initial diagnosis, 
~50% will eventually manifest distant tumors, primarily in 
the liver. Traditional staging methods that use clinical and 
histologic prognostic factors, such as the American Joint 
Committee on Cancer (AJCC) TNM system, can be used 
to stratify patients into general risk categories, but they do 
not provide sufficient predictive accuracy to be used for 
patient care.6 Based on AJCC and National Comprehensive 
Cancer Network (NCCN)7 cancer management guidelines, 
a 50% risk of metastasis (or recurrence) generally correlates 
with Stage III disease, the closest example being cutane-
ous melanoma, and stage III disease is uniformly treated 
with high-intensity imaging and, when available, adjuvant 
chemotherapy, targeted therapy, or radiotherapy. Given 
the poor accuracy of the TNM staging system for UM, the 
management of UM patients has been historically variable, 
owing to the lack of clearly defined treatment guidelines. 
As a consequence, management of all patients as high-risk 
for tumor metastasis in some clinical practices may result 
in overmanagement of patients who were actually low-risk. 
Conversely, in other clinical practices, high-risk patients may 
be relatively undermanaged.
Loss of chromosome 3 is one of the key early cytoge-
netic alterations associated with more aggressive UM,8 and 
monosomy of chromosome 3 in as little as 6% of tumor 
cells significantly increases the risk of UM metastasis.9 
However, intratumoral heterogeneity for monosomy 3 is a 
frequent occurrence that complicates accurate detection and 
is understandable, given that the majority of tumor specimens 
are obtained from a single pass fine-needle aspiration biopsy 
(FNAB).10–12 This FNAB approach is further complicated 
by the need for relatively large tumor samples, in order to 
perform the most common chromosomal detection methods, 
such as fluorescent in situ hybridization (FISH). As a result, 
technical failure in FNAB specimens has been reported in 
as many as 50% of cases.13–15
More recently, gene expression profiling (GEP) of UM has 
gained diagnostic acceptance among ocular oncologists.3,4,16 
GEP takes a “snapshot” of the tumor microenvironment that 
can be used to predict the metastatic potential of the tumor. 
Because tumor sample requirements are generally lower for 
GEP assay, it has a lower technical failure rate than chro-
mosomal assays.17 GEP has been reported in multicenter 
studies to have superior predictive results versus clinical, 
pathological, or chromosomal analyses. 3,4,8,16
Molecular analysis of UM requires FNAB samples. 
However, few reports exist in the medical literature docu-
menting the specific FNAB practices used by ocular oncolo-
gists in UM patients. Even though molecular testing has been 
concluded to be a clinically significant prognostic factor, 
recommended by the AJCC,18 there are few data document-
ing the current frequency and uses of molecular tests in 
the UM patient population. The availability of validated, 
accurate prognostic information may impact the selection 
of a management or treatment plan, including surveillance, 
referral, and therapy initiation within the clinic or clinical 
trial environment that matches metastatic risk. The intent of 
this investigation is to assess the current clinical practices 
for UM and the impact of molecular prognostic testing on 
treatment decisions through (1) focused surveys among 
ophthalomologists who diagnose and treat UM patients, 
and (2) a sequential review of limited medical records and 
known documented policies for all Medicare beneficiaries 
whose GEP tests were successfully performed and records 
were available in 2012.
Methods
Medicare medical records review
A retrospective, treatment decision impact analysis of the 
medical records of patients for whom UM GEP testing was 
ordered and processed for routine clinical use in 2012 was 
performed. These medical records were acquired by Castle 
Biosciences, Inc., (Friendswood, TX) to fulfill Medicare 
requirements for medical record submission during insur-
ance claims submissions and appeals. The medical chart 
records were limited to the timeframe, including diagnosis 
of UM through approximately 12 weeks following primary 
eye tumor treatment. The Medicare patients had been treated 
by one of 37 ophthalmologists in the US. Only data related 
to basic demographics, UM tumor pathology and diagnosis, 
clinical surveillance practices, and institutional treatment 
policies were extracted from the records. Documented medi-
cal policy statements pertaining to use of prognostic testing 
results were also included. This study was approved by the 
Western Institutional Review Board, Olympia, WA. The 
data were analyzed by descriptive statistics. Fisher’s exact 
test was used to analyze the data for GEP Class  versus 1) 
surveillance intensity, 2) oncology referral rates, and 3) 
adjuvant treatment.
For both the medical records review and the clinician 
survey, high-intensity surveillance of UM patients was 
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defined as clinical visits every 3–6 months, liver function 
tests every 3–6 months, and liver imaging/systemic evalua-
tion (eg, computed tomography [CT], ultrasound, magnetic 
resonance imaging [MRI]) every 3–6 months. Low-intensity 
surveillance of UM patients was defined as clinical visits 
every 6–12 months and liver function tests, with or without 
some type of hepatic imaging, once a year.
surveys of clinicians
Two surveys were performed, one in 2012 and the other 
in 2013/14. In 2012, ocular oncologists (ophthalmologists 
with subspecialty training in ocular oncology via retina, 
ophthalmic pathology, or ocular oncology fellowships) 
treating UM in North America, South America, and Europe 
were invited to participate anonymously in a 24-question 
survey that explored the use of FNAB and molecular 
diagnostic tests in their clinical management of UM cases. 
This survey was conducted in response to an invitation 
from the American Association of Ophthalmologists to the 
lead author (Thomas M Aaberg Jr) to give a plenary talk 
on “Practical Approaches to Genetic Diagnosis for Ocular 
Melanoma” at their 2012 Retina Subspecialty Day meeting 
in Chicago, IL.
At the end of 2013/beginning of 2014, ocular oncolo-
gists treating UM in the US were invited to participate 
anonymously in a 23-question survey that explored the use of 
radiotherapy and molecular diagnostic testing of UM tumor 
biopsies in current clinical practice. The follow-up study was 
conducted to address topics not covered in the first survey, to 
investigate whether or not any changing trends in patient care 
could be detected, and to attempt to expand the respondent 
pool. The invitees included all known ocular specialists in 
practice at the time of each survey. The list of potential sur-
vey ocular oncologists was developed by referring to several 
ophthalmology association membership listings and through 
personal knowledge of the field by the authors, based on 
practice patterns of clinicians who diagnosed and managed 
UM patients. An online survey tool was used to capture 
responses. The survey questions and data analyses were 
developed by the authors. Survey responses were analyzed 
by descriptive statistics and frequency analyses (percent-
ages, Tukey, histograms), with descriptive presentation of 
essay answers.
Results
Medicare medical records review
There were 191 evaluable Medicare medical records 
(of 195 total beneficiaries tested) for UM patients treated by 
37 diagnosing physicians (Figure 1). The evaluable patient 
cohort was 57% male with a mean age of 72±8 years (± 
standard deviation). Fifty-eight percent of the patients were 
GEP Class 1 and 42% were GEP Class 2. Of these cohorts, 
91% of the Class 1 and 84% of the Class 2 tumor samples 
were comprised of FNAB, with the remainder from formalin-
fixed, paraffin-embedded enucleation tissue.
surveys of clinicians: general practices
Fifty out of the 109 queried ocular oncologists participated in 
the 2012 survey designed to assess the prevalence of FNAB 
and molecular diagnostic tests for managing the treatment 
of UM patients (46% response rate). The median annual 
caseload of new UM patients for each ocular oncologist 
was 35 (mean ± standard error of the mean [SEM]: 56±11) 
(Figure 2A). The majority (82%) performed some type of 
cellular and/or molecular analysis of UM cases, requiring 
the use of tumor tissue FNAB. Eighty-seven percent of 
respondents (32 out of 37) analyzed all biopsy tumor samples 
from both FNAB and enucleated eyes, while the remainder 
analyzed only enucleated eyes. Safety concerns relating to 
tumor location or other features rendered a median of 10% 
of the UM patients ineligible for a biopsy procedure across 
the respondents’ clinical practices.
Thirty-five out of the 72 queried ocular specialists partici-
pated in the 2014 survey (49% response rate). Twelve (34%) 
had not participated in the 2012 survey, seven (20%) were 
unsure, and 16 (46%) had previously participated in the 2012 
survey. Of the respondents, 49% were based at a university, 
46% were based in private practice, and two (5%) were 
based at both. The majority (66%) were the only physician 
in their practice group to treat UM, with 29% indicating that 
one other colleague in their practice group also treated UM, 
and only two respondents indicating that two or more other 
colleagues treated UM. The median annual caseload of new 
UM patients for each ocular oncologist was 30 (mean ± SEM: 
40±5) (Figure 2B). GEP was offered to patients by 88% of 
respondents (30 out of 34), while 24% offered chromosome 
three analysis (CHR3) (8 out of 34).
surveys of clinicians: surgical techniques 
and radiotherapy
As illustrated in Figure 2A, respondents in the 2012 survey 
performed a median of 15 UM biopsies per year (mean: 
27±7). Almost all (94%) were conducted at the time of plaque 
placement, enucleation, or clip placement. Most respondents 
biopsied only one site (69%), while 20% biopsied two sites. 
Few biopsied more than two sites (11%).






















































Figure 1 summary of Medicare medical records review.
Notes: There were 191 evaluable Medicare medical records for UM patients treated by 37 diagnosing physicians. High-intensity surveillance of UM patients was defined 
as clinical visits every 3–6 months, liver function tests every 3–6 months, and liver imaging/systemic evaluation (eg, CT, ultrasound, Mri) every 3–6 months. low-intensity 
surveillance of UM patients was defined as clinical visits every 6–12 months and liver function tests, with some type of hepatic imaging, at least once a year.







































































Figure 2 number of new UM cases and biopsy activity per responding physician, collected from the clinician surveys in 2012 (number of participating physicians (n) =50) and 
early 2014 (number of participating physicians (n) =35).
Notes: Box plots with Tukey analysis. (A) Data derived from the 2012 survey: number of new UM cases per reporting physician (median: 35, mean: 56) and annual number 
of biopsies (median: 15, mean: 27). (B) Data derived from the 2014 survey: number of new UM cases per reporting physician (median: 30, mean: 40).
Abbreviation: UM, uveal melanoma.
The majority of respondents in the 2012 survey used a 25 
(57%) or 27 (43%) gauge needle for the FNAB, and 77% used 
flexible tubing between the needle hub and a ten cc syringe, to 
stabilize the needle. Most respondents (74%) did not use a vit-
rector for the biopsy procedure, although 9% used one for 50% 
or more of their surgeries. A median of 80% of biopsy proce-
dures were performed transscleral (mean ± SEM: 70±5) and 
a median of 20% were performed transvitreal (mean ± SEM: 
30±5). Choice of approach was generally determined by tumor 
location and depth, although several respondents indicated 
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better results in general whenever a transscleral approach 
was possible. Very posterior tumors were more likely to be 
approached transvitreally. There was almost an even split 
between biopsy procedures performed via a scleral window 
(57%) or via a full thickness sclera (43%). Approximately half 
of respondents (54%) sealed the biopsy site, while the other 
half did not. FNAB specimens were usually preserved in the 
fixative kit provided by the testing lab (83%).
In the 2014 survey, when patients were amenable to radio-
therapy, 94% of respondents used brachytherapy primarily or 
exclusively (32 out of 34) and two used proton beam therapy. 
Patients undergoing radiotherapy were offered some type of 
molecular analysis of their pre-radiation tumor biopsy tissue 
“nearly always” by 76% of respondents (N=35) (Figure 3A). 
Four of the five respondents who “never or rarely” offered 
molecular analysis cited safety concerns. Three stated that 
the information would not alter their patients’ management, 
and three respondents gave other reasons. One perceived the 
biopsy procedure as technically difficult. One believed this 
type of analysis should only be used in an investigational set-
ting, not in routine clinical practice. The other respondent did 
not believe the information would be useful to the patient.
Similar to the 2012 survey, a minority of UM patients 
(median: 12.5%; mean: 22%±5%) in the 2014 survey were 
considered ineligible for a tumor biopsy procedure, due to 
safety concerns associated with the surgery, such as small 
tumor size or tumor location (N=32). Of the remaining radio-
therapy patients, for whom there was no biopsy safety con-
cern and for whom cytogenetic or GEP analyses were offered, 
a median of 90% agreed to testing (mean: 69%±6%). The 
primary reasons for declining the tests were that the patient 
did not want to know (65%; N=26), safety concerns about the 
procedure (23%), the cost of the testing (two respondents), 
or concerns about discrimination against them by insurance 
companies (one respondent).
surveys of clinicians: tumor biopsy 
analyses
The majority of respondents (77%) in the 2012 survey offered 
all patients a biopsy and some form of molecular tumor 
analysis. Some of the reasons for not offering a biopsy and 
testing included: 1) the tumor being too small and close to the 
macula, 2) the lack of treatments proven to improve clinical 
outcomes, 3) vision loss outweighing any potential benefits, 
and 4) lack of coverage for the procedures by some medi-
cal insurance carriers. FNAB specimens were analyzed by 
cytology (49%), chromosomal analysis (20%), and/or GEP 
(89%) (Figure 4). Six percent were used only for research 
purposes. Fourteen percent were preserved in a tissue bank 
or used for a combination of research and other tests. Among 
respondents to the 2012 survey, 19% offered CHR3 to most 
of their UM patients; 13.5% offered CHR3 to all patients, and 
the majority (65%) offered CHR3 to none of their patients 
(Figure 5A). Seventy-eight percent of respondents offered 
molecular testing using GEP analysis to most of their UM 
patients; 54.1% offered GEP analysis to all patients, and 
8% offered GEP analysis to none of their patients. The 2014 
survey suggested a shift towards more respondents offer-
ing all their patients GEP and none of their patients CHR3 
(Figure 5B). The median percentage of patients in the 2012 
survey who declined to have their tumor analyzed at all was 
25% (mean 38%±6%). Elderly patients were generally not 
interested, some patients feared loss of their medical insur-








































































Figure 3 Distribution of physicians according to the frequency with which they offer some type of tumor analysis (Chr3 or geP analysis) by (A) patients undergoing 
radiotherapy, or (B) patients undergoing enucleation.
Notes: Data derived from the 2014 survey. n=35.
Abbreviations: UM, uveal melanoma; CHR3, chromosome 3 analysis; GEP, gene expression profiling.
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records, and some feared the biopsy procedure would hasten 
tumor metastasis or cause additional morbidities. The general 
absence of proven treatment interventions was also a patient 
reason for declining biopsy and testing.
In the 2014 study, patients undergoing enucleation for 
UM were offered some type of cytogenetic (CHR3) and/
or molecular profiling analysis (GEP) of the tumor by 83% 
of the respondents (Figure 3B). Reasons given by the four 
respondents who never offered these analyses were: 1) the 
perceived technical difficulty of the biopsy procedure, 2) did 
not believe the information would be useful to the patients, 
and 3) did not believe the information would be useful to 
the respondent. The option of having the testing done after 
referral to a surgeon was discussed with UM patients by 
three respondents who did not offer the testing through their 
own practice.
effects on treatment strategy
Perhaps most importantly, 74% of respondents in the 2012 
survey used the information obtained from the FNAB 
specimens and cytogenetic or GEP analyses to change the 
frequency of metastatic disease surveillance (Figure 6). 
Twenty-one percent (8 out of 39) did not use the information 
in the management of their patients, and two of these respon-
dents referred their UM patients to oncologists, who did use 
the genetic information. Four respondents who did not use the 
cytogenetic data cited the current lack of effective therapeutic 
options. For patients at higher risk of metastasis, 15% also 
offered prophylactic therapy and 23% offered participation 
in a clinical trial of an investigational therapy.
Similarly, 79% of respondents in the 2014 survey (N=33) 
used the information obtained from the cytogenetic or GEP 
analyses to change their clinical practice, such as adjusting 
the frequency of metastatic disease surveillance, referral to 
medical oncology for follow-up, and/or counseling/referral 
regarding adjuvant treatment or clinical trials. Patients 
with low metastatic risk, based on CHR3 or a Class 1 GEP 
result, were generally assigned to less frequent (every 6 or 
12 months) and less intensive clinical visits. Most respon-
dents performed liver function tests and some type of hepatic 
imaging (eg, CT, ultrasound, MRI) at least once a year 
in low-risk UM patients. Only one respondent counseled 
or referred low-risk patients for adjuvant clinical trials or 
adjuvant treatment. In contrast, patients with high metastatic 

































Figure 4 Test services performed on biopsy specimens.
Notes: The majority of clinicians offered UM patients a biopsy and some form of 
molecular tumor analysis. n=35.
Abbreviations: GEP, gene expression profiling; UM, uveal melanoma.























































Figure 5 histograms illustrating the distribution of UM patients offered each type of diagnostic test.
Notes: (A) Data derived from the 2012 survey; n=37. (B) Data derived from the 2014 survey; n=34.
Abbreviations: UM, uveal melanoma; GEP, gene expression profiling.
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to more frequent surveillance, with hepatic imaging or liver 
function testing, often alternating quarterly. If the diagnos-
ing physician was not an oncology specialist, then high-risk 
patients were referred to one. Only one respondent said they 
did not counsel or refer high-risk patients for adjuvant clinical 
trials or adjuvant treatment.
When asked their thoughts concerning a low-morbidity, 
low-toxicity clinical trial in the future that was designed as 
an adjuvant treatment protocol, 38% believed the protocol 
should be offered to all UM patients and 59% believed the 
protocol should be offered only to UM patients at high risk 
of tumor metastasis, based on cytogenetic or GEP analyses 
(N=34). Five of the respondents (15%) who believed only 
high-risk patients should be offered this type of clinical trial 
would also refer patients who were classified as high-risk 
based on clinical findings (ie, tumor size, cell type, etc) to 
this type of clinical trial. None of the respondents would fail 
to offer this alternative to their high-risk patients.
Respondents were more cautious about referring UM 
patients to a high-morbidity, high-toxicity clinical trial that 
was designed as an adjuvant treatment protocol (N=34). Only 
9% agreed that it should be offered to all UM patients. The 
majority (74%) believe that patients classified as high-risk, 
based on cytogenetic or GEP analyses, should be offered 
this alternative. Six of these respondents would also offer it 
to UM patients classified as high-risk based on clinical find-
ings, and an additional two respondents would offer this type 
of clinical trial to UM patients classified as high-risk based 
only on clinical findings. There were also four respondents 
(12%) who would not offer this type of clinical trial to any 
UM patient.
Of the 191 evaluable patients in the Medicare records 
review, there were 88 (46%) with documented medical treat-
ment actions in their medical records or with documented 
institutional medical policies related to surveillance plans 
(Figure 1). All of the GEP Class 1 UM patients were treated 
with a low-intensity surveillance plan (Figure 6). In contrast, 
all of the GEP Class 2 UM patients were treated with a 
high-intensity surveillance plan (P0.0001 versus Class 1 
surveillance). Comments on GEP Class 1 surveillance prac-
tices from patient medical charts indicated that physicians 
advised liver function tests on an annual or biannual basis, 
liver imaging on an annual basis, and an annual systemic 
evaluation or no surveillance at all, due to the low risk of 
UM tumor metastasis. In contrast, GEP Class 2 surveillance 
practices from patient medical charts indicated that physi-
cians advised liver function tests every 3, 4, or 6 months, 
and liver imaging/systemic evaluation every 3 to 6 months. 
The majority of records indicated a “known policy” of more 
frequent and intensive surveillance for Class 2 patients. Of 
the 191 evaluable patients, there were 36 (19%) with infor-
mation concerning referrals to medical oncology after initial 
diagnosis. All 23 Class 2 patients were referred to medical 
oncology, but none of the 13 Class 1 patients (P0.0001 
versus Class 1). Similarly, only Class 2 patients were recom-
mended for adjunctive treatment regimens.
Discussion
Concomitant with the completion of the GEP test prospective, 
multicenter clinical validation study, molecular testing for 
analyzing uveal melanomas has become more easily acces-
sible over the past few years. However, the frequency of use 
of these tests by ocular oncologists and the clinical applica-
tion of these analyses have not been previously assessed. Our 
surveys found a number of interesting observations about 
current clinical practices.
In the first survey the physician respondents practiced 
in North America, South America, and Europe; although, it 
should be noted that a commercial GEP test is not currently 
available in Europe or South America. Therefore, the 2014 
survey only queried physicians with clinical practices in the 
United States. In this latest survey, the respondents were 
Medicare records review 2012 clinician survey
Low intensity surveillance
High intensity surveillance


























































Figure 6 Clinical use of test data for patient management.
Notes: High-intensity surveillance of UM patients was defined as clinical visits 
every 3–6 months, liver function tests every 3–6 months, and liver imaging/systemic 
evaluation (eg, CT, ultrasound, Mri) every 3–6 months. low-intensity surveillance 
of UM patients was defined as clinical visits every 6–12 months and liver function 
tests with some type of hepatic imaging at least once a year. records review: n=88. 
survey: n=39.
Abbreviations: UM, uveal melanoma; CT, computed tomography; Mri, magnetic 
resonance imaging.
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evenly split between university-based and private practices, 
and most were the only physician in their practice group to 
treat UM patients. Overall, there was a wide range in the 
UM caseloads among the different clinical practices. Most 
handled 30–35 new cases a year, but a few had 100 or more, 
for an estimated total of 1,389 in the 2014 survey. Based on 
the US National Cancer Institute estimate of 4.3 new cases 
of UM per million US adults a year, the most recent survey 
may represent all or nearly all of the annual UM caseload in 
the US in 2013.19,20 In both survey groups, more than 75% 
of respondents offered molecular testing of tumor biopsy 
samples to most or all of their UM patients. Safety concerns 
rendered a median 10% of UM patients ineligible for a biopsy 
procedure. Of the remaining patients, for whom there was 
no biopsy safety concern and for whom CHR3 or GEP were 
offered, the majority agreed to testing. The primary reasons 
patients declined testing were that they did not want to know, 
they had safety concerns about the biopsy procedure, or they 
had concerns about discrimination against them by insurance 
companies. Elderly patients were generally less interested.
The physicians preferred a 25 or 27 gauge needle for 
FNAB of UM tumors, generally attached to a 10 cc syringe 
via flexible tubing. The choice of surgical approach was usu-
ally determined by tumor location and depth, although several 
respondents indicated better results in general whenever a 
transscleral approach was possible. Very posterior tumors 
were more likely to be approached transvitreally. There was 
almost an even split between biopsy procedures performed 
via a scleral window or via a full thickness sclera. When the 
tumors were amenable to radiotherapy, the vast majority 
were treated using brachytherapy.
As might be expected with the widespread adoption 
of a new technology, the majority of physicians used the 
information obtained from molecular analyses to change 
patient management, specifically the frequency of metastatic 
disease surveillance. The ability to rule out high-risk disease 
represents an important shift in UM patient management. 
According to the survey data, patients at high risk for tumor 
metastases were monitored every 3–6 months, compared with 
every 6–12 months for low-risk patients. The risk categories 
generated from this type of testing were also used to identify 
UM patients (high-risk) most likely to be referred to, and 
most likely to benefit from, investigational clinical trials.
The Medicare chart and policy review results parallel the 
results from the two blinded clinician surveys. Specifically, 
of cases for which there was documented evidence of clinical 
use of the results and/or known physician policy, 100% of 
patients with a low-risk Class 1 result were managed by a 
low-intensity surveillance plan that was primarily defined as 
liver function tests without (or with) abdominal ultrasound at 
a frequency of one or two times per year. In contrast, 100% 
of patients with a high-risk Class 2 result were managed by 
a high-intensity surveillance plan, primarily defined as liver 
function tests and abdominal ultrasound, CT, and/or positron 
emission tomography (PET) at a frequency of 2 to 4 times per 
year. Additionally, more Class 2 patients received referrals to 
medical oncology and/or adjuvant treatment protocols.
In agreement with the results obtained in the clinician 
surveys and the Medicare chart and policy study, molecular 
diagnostic testing (specifically GEP) was shown to have a 
significant impact on clinical treatment strategy.4 Clinicians 
used these data to “rule out” high-risk disease. When GEP 
testing was used, nearly all patients with GEP Class 1 UM 
were managed with a low-intensity surveillance paradigm. 
In contrast, almost all Class 2 UM patients received the 
standard high-intensity surveillance. Consistent with their 
higher-risk disease, Class 2 UM patients were more likely 
to be referred to a medical oncologist for possible clinical 
trial enrollment. Thus, the GEP results may enable low-risk 
patients to avoid unnecessary monitoring, inconvenience 
and cost, and the adverse personal effects of worrying about 
their disease. These results also provided high-risk patients 
and their caregivers with important information for making 
informed decisions about their own health care. Recently, 
Correa and Augsburger21 reported data showing that 29% 
of Class 2 GEP UM patients, but only 6% of Class 1 GEP 
patients, had tumor metastases at a median follow-up time of 
32.5 months (total sample size: 158). Also, GEP classification 
was “substantially better” than cytologic classification for 
predicting metastasis and metastatic death. Together, these 
data support a recommendation for more intensive surveil-
lance in Class 2 GEP patients, which will hopefully one day 
translate into better mortality outcomes.
Overall, the data in this report support the conclusion that 
molecular analysis, including GEP and chromosomal analysis, 
have been widely accepted and adopted for uveal melanoma 
treatment decisions. In addition to the impact on surveillance 
and referral management, such information is likely to be 
required for entry into future clinical trials involving adjuvant 
therapy at major medical centers.22 The authors recognize that 
there is no strong data suggesting that more intensive surveil-
lance improves survival outcomes. However, the recent data 
showing benefit using immunotherapy 23 and targeted therapy 24 
is encouraging in that these clinical trials may advance imme-
diate, adjuvant therapy options for UM patients over the next 
few years and ultimately reduce mortality rates.
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Supplementary materials
Table S1 2012 survey questions
 1 how many new cases of uveal melanoma do you see annually? (respondent n=50)
 2  Do you perform some type of cellular and/or molecular analysis of uveal malignant melanoma which requires a fine needle biopsy?  
(respondent n=50)
 3 how many uveal melanoma patients (%) are not eligible for biopsy due to safety concerns? (respondent n=37)
 4 For eligible patients do you perform analysis for: (respondent n=37)
a. enucleated eyes only
b. all cases
 5 What percent of uveal melanoma cases do you offer cytogenetic (chromosome 3) testing? (respondent n=37)
 6 What percent of uveal melanoma cases do you offer molecular testing (DecisionDx-UM gene expression profile)? (Respondent N=37)
 7 how many biopsies for uveal melanoma do you perform annually? (respondent n=37)
 8 in what % of cases do you employ use of a vitrector for biopsy procedures? (respondent n=35)
 9 What size needle gauge do you use to biopsy the tumor? (respondent n=35)
10 Do you utilize flexible tubing between the needle hub and the syringe to stabilize the needle position? (Respondent N=27)
11 What size syringe do you use in order to create vacuum? (respondent n=27)
12 Do you perform the biopsy via a scleral window or via full thickness sclera? (respondent n=35)
13 What percent of biopsies are performed transscleral? (respondent n=35)
14 What percent of biopsies are performed transvitreal? (respondent n=35)
15 if you perform both transscleral and transvitreal biopsies, what factors contribute to your decision process? (respondent n=35)
16 after the biopsy is performed do you “seal” the biopsy site? (respondent n=35)
17 is the biopsy performed... (respondent n=35)
a. at the time of plaque placement, enucleation or clip placement
b. as a separate procedure
18 how many tumor sites do you biopsy? (respondent n=24)
19 What testing do you perform with your biopsy material? (respondent n=35)
20 What fixative do you use (ex, fixative provided by processing lab, cytolyte, formalin)? (Respondent N=35)
21 Do you offer all patients biopsy and analysis of the tumor? (respondent n=39)
22 What percentage of patients decline the offer for testing? (respondent n=39)
23 What reasons are given for declining testing? (respondent n=39)
24 how do you use the information clinically? (respondent n=39)
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Table S2 2014 survey questions
 1  Did you participate in the July 2012 survey that Dr aaberg distributed in preparation for the 2012 retina sub-specialty day presentation? 
(respondent n=35)
 2 are you: (respondent n=32)
    •  University based
    •  Private practice
    •  government based (ex: Veterans administration)
    •  Other ____________
 3 Within your practice group, how many physicians treat primary uveal melanoma? (respondent n=35)
 4  how many new cases of uveal melanoma do you personally see annually (eg, if in a practice group with more than one physician who treats 
uveal melanoma, only include your direct new cases)? (respondent n=35)
 5 For patients amenable to radiotherapy, do you use: (respondent n=34)
    •  Brachytherapy 
    •  Proton Beam
    •  i have access to both modalities and use both equally
    •  i have access to both modalities and use Proton Beam principally
    •  i have access to both modalities and use Brachytherapy principally
    •  Other ____________
 6  For patients undergoing radiotherapy for ocular melanoma, do you offer some type of cytogenetic (chromosome 3) and/or molecular profiling 
analysis (the gene expression profile test) of the tumor which requires a biopsy? (Respondent N=35)
    •  never or rarely
    •  less than 33%
    •  33%–85%
    •  nearly always
 7 if you answered “never or rarely” to question #5, you do not offer testing because (please check all answers that apply): (respondent n=5)
    •  safety concerns, such as increased risk of orbital seeding or risk of vision loss due to hemorrhage
    •  Perceive the biopsy procedure as technically difficult
    •  The information obtained will not alter my management decisions
    •  Do not believe the information provided to be useful to me
    •  Do not believe the information provided to be useful to the patient
    •  Believe the testing should only be used in an investigational setting
    •  Other ____________
 8  For patients undergoing enucleation for ocular melanoma, do you offer some type of cytogenetic (chromosome 3 – disomy or monosomy) and/
or molecular profiling analysis (the gene expression profile test – Class 1 or Class 2) of the tumor? (Respondent N=35)
    •  never or rarely
    •  less than 33%
    •  33%–85%
    •  nearly always
 9 if you answered “never or rarely” to question #7 you do not offer testing because (please check all answers that apply): (respondent n=2)
    •  safety concerns, such as increased risk of orbital seeding or risk of vision loss due to hemorrhage
    •  Perceive the biopsy procedure as technically difficult
    •  The information obtained will not alter my management decisions
    •  Do not believe the information provided to be useful to me
    •  Do not believe the information provided to be useful to the patient
    •  Believe the testing should only be used in an investigational setting
    •  Other ____________
10  if you do not offer any form of testing in any case, do you still discuss the option with the patient and refer the patient to a center that does 
perform testing? (respondent n=31)
    •  Yes
    •  no
    •  Does not apply, because i do offer testing
11  if you do not offer any form of testing in any case, please complete this question but you do not have to continue the questionnaire.  Will you 
consider performing testing in the future? if so, what would have to occur? (respondent n=26)
    •  no
    •  Yes, ____________
    •  Does not apply, because i do offer testing
(Continued)
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Table S2 (Continued)
12  What percentage of your radiotherapy patients are not eligible for biopsy due to safety concerns related to the biopsy procedure, such as tumor 
location or small size? (respondent n=32)
13  Of the remaining radiotherapy patients for whom there is no biopsy safety concern and for whom you offer cytogenetic or gene expression 
profiling analysis of the tumor, what percentage agrees to testing? (Respondent N=32)
14  What is the principle reason that patients decline testing (select only what you consider the number one reason even though other reasons may 
apply)? (respondent n=26)
   •  safety concerns, for example: increased risk of orbital seeding, risk of vision loss due to hemorrhage.
   •  The patient “does not want to know”
   •   Concerned that the information may be used against them, example: disability or life insurance company may deem the patients as 
“uninsurable” if they have a “high-risk” tumor.
   •  Cost of testing
   •  Other ____________
15 Which testing do you offer? (check all that apply) (respondent n=34)
   •  Cytogenetics (chromosome 3 analysis)
   •  Molecular profiling diagnostics (the gene expression profile test)
   •  Other ____________
16 For those patients that have testing, what percent do you offer cytogenetic (chromosome 3) testing? (respondent n=32)
17 For those patients that have testing, what percent do you offer molecular profiling diagnostics (the gene expression profile test)? (Respondent N=34)
18  For those patients who have testing performed, do you use the information clinically (such as metastatic surveillance approach, referral to 
medical oncology for follow-up, or counsel/refer regarding adjuvant treatment or adjuvant clinical trials)? (respondent n=33)
19  if you answered “Yes” to question 18 regarding metastatic surveillance approach, please describe your general approach (eg, frequency and type 
of testing or imaging) for patients with low risk Class 1/disomy 3 test results. (respondent n=24)
20  if you answered “Yes” to question 18 regarding metastatic surveillance approach, please describe your general approach (eg, frequency and type 
of testing or imaging) for patients with high-risk Class 2/monosomy 3 test results. (respondent n=24)
21 if you answered “Yes” to question 18 regarding counseling regarding adjuvant treatment options or adjuvant clinical trials (respondent n=27):
   •  Do you counsel or refer low risk Class 1/disomy 3 patients for adjuvant clinical trials or adjuvant treatment?
   •  Do you counsel or refer high-risk Class 2/monosomy 3 patients for adjuvant clinical trials or adjuvant treatment?
22  Thinking about future clinical trials, if a low morbidity risk adjuvant treatment protocol (that is, a treatment that has a relatively low toxicity or 
side effect profile) was available for uveal melanoma patients, do you believe (Respondent N=34):
   •  The protocol should be offered to all uveal melanoma patients
   •  The protocol should be offered only to patients with high-risk features based on clinical findings (ie, tumor size, cell type, etc).
   •  The protocol should be offered only to patients with high-risk features based on gene expression profile diagnostics and/or cytogenetics.
   •  The protocol should not be offered to any patient.
23  Thinking about future clinical trials, if a high morbidity risk adjuvant treatment protocol (that is, a treatment that has a relatively high toxicity or 
side effect profile) was available for uveal melanoma patients, do you believe (Respondent N=34):
   •  The protocol should be offered to all uveal melanoma patients
   •  The protocol should be offered only to patients with high-risk features based on clinical findings (ie, tumor size, cell type, etc).
   •  The protocol should be offered only to patients with high-risk features based on molecular diagnostics and/or cytogenetics.
   •  The protocol should not be offered to any patient.
